GuatemalaTuberculosis profile
Population  2015 16 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.32 (0.3–0.35) 2 (1.8–2.2)
Mortality (HIV+TB only) 0.05 (<0.01–0.14) 0.31 (0.04–0.85)
Incidence  (includes HIV+TB) 4.2 (3.2–5.2) 25 (20–32)
Incidence (HIV+TB only) 0.27 (0.21–0.34) 1.7 (1.3–2.1)
Incidence (MDR/RR-TB)** 0.23 (0.15–0.31) 1.4 (0.92–1.9)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.33 (0.19–0.47) 1.5 (0.91–2) 1.8 (1.1–2.5)
Males 0.29 (0.19–0.4) 2.1 (1.5–2.6) 2.3 (1.7–3)
Total 0.62 (0.44–0.81) 3.5 (2.9–4.1) 4.2 (3.2–5.2)
TB case notifications, 2015  
Total cases notified 3 381
Total new and relapse 3 325
          - % tested with rapid diagnostics at time of diagnosis 5%
          - % with known HIV status 92%
          - % pulmonary 93%
          - % bacteriologically confirmed among pulmonary 83%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.07–0.12)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 195 6%
          - on antiretroviral therapy 167 86%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  180
(130–230)
Estimated % of TB cases with MDR/RR-TB 4.2% (2.6–5.8) 29% (21–37)  
% notified tested for rifampicin resistance 14% 52% 548
MDR/RR-TB cases tested for resistance to second-line drugs   6
Laboratory-confirmed cases MDR/RR-TB: 27, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 40, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 85% 2 756
Previously treated cases, excluding relapse, registered in 2014 53% 55
HIV-positive TB cases, all types, registered in 2014 71% 194
MDR/RR-TB cases started on second-line treatment in 2013 78% 27
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 14%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
50% (46–55)
TB financing, 2016  
National TB budget (US$ millions) 4.7
Funding source: 44% domestic, 54% international, 2% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data